Ignite Creation Date:
2024-05-05 @ 7:46 PM
Last Modification Date:
2024-10-26 @ 9:53 AM
Study NCT ID:
NCT00739375
Status:
COMPLETED
Last Update Posted:
2013-12-13
First Post:
2008-08-17
Brief Title:
The Effect of Blood Flow in the Maturing Arteriovenous Access for Hemodialysis on the Development of Pulmonary Hypertension
Sponsor:
Shaare Zedek Medical Center
Organization:
Shaare Zedek Medical Center
Study Overview
Official Title:
The Effect of Blood Flow in the Maturing Arteriovenous Access for Hemodialysis on the Development of Pulmonary Hypertension
Status:
COMPLETED
Status Verified Date:
2013-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Pulmonary hypertension PHT is an elevation of pulmonary arterial pressure PAP that can be the result of heart lung or systemic disease PHT also complicates chronic hemodialysis HD therapy immediately after the creation of an arteriovenous AV access even before starting HD therapy It tends to regress after temporary AV access closure and after successful kidney transplantation Affected patients have significantly higher cardiac output This syndrome is associated with a statistically significant survival disadvantage The laboratory hallmark of this syndrome is reduced basal and stimulatory nitric oxide NO levels It appears that patients with end-stage renal disease ESRD acquire endothelial dysfunction that reduces the ability of their pulmonary vessels to accommodate the AV access-mediated elevated cardiac output exacerbating the PHT Doppler echocardiographic screening of ESRD patients scheduled for HD therapy for the occurrence of PH is indicated Early diagnosis enables timely intervention currently limited to changing dialysis modality such as peritoneal dialysis or referring for kidney transplantationAn echocardiographic diagnosis of pulmonary hypertension PHT is made when the systolic pulmonary arterial pressure PAP exceeds normal values 30 mmHg In mild PHT PAP values range up to 45 mmHg in moderate PHT PAP is between 45 and 65 mmHg and in severe PHT PAP values are greater than 65 mmHg Systolic PAP equals cardiac output times pulmonary vascular resistance PVR ie PAP cardiac output PVR Increased cardiac output by itself does not cause PH because of the enormous capacity of the pulmonary circulation to accommodate the increase in blood flow Therefore development of PHT requires pathologic marked elevation of pulmonary vascular resistance The presence of PH may reflect serious pulmonary vascular disease which can be progressive and fatal Consequently an accurate diagnosis of the cause of PHT is essential in order to establish an effective treatment program Pulmonary hypertension can occur from diverse etiologies In 1996 we first noted unexplained PH in some long-term hemodialysis HD patients during an epidemiologic study of this disorder Nakhoul F and Yigla M Rambam Medical Cemter-Haifa It was assumed that their PHT was related to end-stage renal disease ESRD or to long-term HD therapy via an arteriovenous AV access
There are several potential explanations for the development of PHT in patients with ESRD Hormonal and metabolic derangement associated with ESRD might lead to vasoconstriction of pulmonary vessels and increased pulmonary vascular resistance Values of PAP may be further increased by high cardiac output resulting from the AV access itself worsened by commonly occurring anemia and fluid overload Despite almost five decades of HD therapy via a surgically created often large hemodynamically significant AV access the long-term impact of this intervention on the pulmonary circulation has received little attention
RD versus AV HD via AV access
Proposed Mechanisms
1 Elevated Parathyroid hormone
2 Metastatic Calcification due to the increase of the calcium-phosphor multiple
3 High cardiac output
4 Nitric oxide-endothelin metabolism
5 A-v Access flow
These observations indicate a role for AV access-mediated elevations in cardiac output in the pathogenesis of PH The correlation between access flow and PAP values has not yet been studied Since patients undergoing HD therapy via AV access had PH that reversed after successful kidney transplantation and after short AV access compression we concluded that both ESRD and AV access-mediated elevated cardiac output are required for the development PH From a physiologic point of view due to the enormous capacity of the pulmonary microcirculation increased cardiac output by itself cannot cause PH It is the inability of the pulmonary circulation of some ESRD patients to accommodate the AV access-mediated elevated cardiac output that leads to the development of PH
There are several potential explanations for the development of PHT in patients with ESRD Hormonal and metabolic derangement associated with ESRD might lead to vasoconstriction of pulmonary vessels and increased pulmonary vascular resistance Values of PAP may be further increased by high cardiac output resulting from the AV access itself worsened by commonly occurring anemia and fluid overload Despite almost five decades of HD therapy via a surgically created often large hemodynamically significant AV access the long-term impact of this intervention on the pulmonary circulation has received little attention
RD versus AV HD via AV access
Proposed Mechanisms
1 Elevated Parathyroid hormone
2 Metastatic Calcification due to the increase of the calcium-phosphor multiple
3 High cardiac output
4 Nitric oxide-endothelin metabolism
5 A-v Access flow
These observations indicate a role for AV access-mediated elevations in cardiac output in the pathogenesis of PH The correlation between access flow and PAP values has not yet been studied Since patients undergoing HD therapy via AV access had PH that reversed after successful kidney transplantation and after short AV access compression we concluded that both ESRD and AV access-mediated elevated cardiac output are required for the development PH From a physiologic point of view due to the enormous capacity of the pulmonary microcirculation increased cardiac output by itself cannot cause PH It is the inability of the pulmonary circulation of some ESRD patients to accommodate the AV access-mediated elevated cardiac output that leads to the development of PH
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None